Engaging Parents, Caregivers, and Schools in the Management of Pediatric Atopic Dermatitis
December 17th 2024Karan Lal, DO, MS, FAAD, discusses how building a collaborative care network between parents, caregivers, and school staff is crucial for successful management of pediatric atopic dermatitis through consistent treatment application, trigger avoidance, and emergency response planning.
Unique Challenges and Considerations for Treating Pediatric Atopic Dermatitis
December 17th 2024A panelist discusses how treating pediatric atopic dermatitis requires special attention to age-appropriate therapies, family education, adherence challenges, and the impact on children’s quality of life, including sleep and social development.
Differentiating Pediatric Atopic Dermatitis from Other Skin Conditions
December 17th 2024Karan Lal, DO, MS, FAAD, discusses how physicians can distinguish pediatric atopic dermatitis from similar skin conditions through key clinical features such as characteristic rash distribution, intense itching, and family history of atopic diseases.
Safety, Efficacy, and Treatment Adherence in Young Patients With Vitiligo
December 12th 2024Karan Lal, DO, MS, FAAD, discusses how to balance safety and efficacy considerations while promoting treatment adherence in young vitiligo patients, focusing on the unique challenges and monitoring requirements for this vulnerable population.
Tailoring Treatments and Counseling Patients With Pediatric Vitiligo
December 12th 2024Karan Lal, DO, MS, FAAD, discusses how to optimize vitiligo management in pediatric patients through personalized treatment selection and age-appropriate counseling strategies that address both the physical and psychosocial aspects of the condition.
Vitiligo Treatment Patterns and Pearls for Adults Versus Pediatric Patients
December 12th 2024Karan Lal, DO, MS, FAAD, discusses how treatment approaches for vitiligo differ between adult and pediatric populations, with experts examining distinct patterns of care, therapeutic considerations, and clinical pearls specific to each age group.
Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis
October 7th 2024Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.
Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis
October 7th 2024Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.
Adult vs Pediatric Plaque Psoriasis Treatment Challenges
September 30th 2024Panelists discuss how limited treatment options, safety concerns, adherence issues, and the lack of long-term data pose significant challenges in effectively managing pediatric vs adult plaque psoriasis, highlighting the need for more research and tailored approaches for this patient population.
Early Diagnosis and Management, Unmet Needs and Treatment Challenges in Pediatric Plaque Psoriasis
September 30th 2024Karan Lal, DO, and Helen T Shin, MD, discuss how early diagnosis of pediatric plaque psoriasis significantly improves management strategies and enhances long-term outcomes by allowing for timely intervention and personalized treatment plans.
Diagnostic Challenges in the Management of Pediatric Plaque Psoriasis
September 23rd 2024Karan Lal, DO, and Helen T Shin, MD, discuss how diagnostic challenges in pediatric plaque psoriasis, such as its similarity to other skin conditions and potential underreporting, can complicate timely identification and appropriate management of the disease in children.